Grifols Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Grifols stock.
View analyst ratings for Grifols or view top-rated stocks.

Wall Street analysts have given Grifols a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Grifols wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Grifols is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Grifols.

Grifols, S.A. (NASDAQ:GRFS) issued its quarterly earnings data on Tuesday, May, 4th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.22 by $0.01. The biotechnology company earned $1.43 billion during the quarter. Grifols had a net margin of 10.78% and a trailing twelve-month return on equity of 9.92%.
View Grifols' earnings history.

Grifols' stock was trading at $20.36 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GRFS stock has decreased by 13.7% and is now trading at $17.57.
View which stocks have been most impacted by COVID-19.

Grifols announced a semi-annual dividend on Wednesday, May 26th. Stockholders of record on Friday, June 4th will be paid a dividend of $0.4385 per share on Monday, June 14th. This represents a yield of 2.6%. The ex-dividend date is Thursday, June 3rd. This is a boost from Grifols's previous semi-annual dividend of $0.14.
View Grifols' dividend history.

Grifols pays an annual dividend of $0.02 per share and currently has a dividend yield of 0.11%. Grifols does not yet have a strong track record of dividend growth. The dividend payout ratio of Grifols is 1.63%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Grifols will have a dividend payout ratio of 1.28% next year. This indicates that Grifols will be able to sustain or increase its dividend.
View Grifols' dividend history.

Grifols shares split on the morning of Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly minted shares were payable to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of Grifols stock prior to the split would have 200 shares after the split.

205 employees have rated Grifols CEO Raimon Grifols and Victor Grifols Deu on Glassdoor.com. Raimon Grifols and Victor Grifols Deu has an approval rating of 68% among Grifols' employees.

Some companies that are related to Grifols include Alexion Pharmaceuticals (ALXN), Astellas Pharma (ALPMY), BeiGene (BGNE), Shiseido (SSDOY), Genmab A/S (GMAB), Royalty Pharma (RPRX), Takeda Pharmaceutical (TKPYY), Genmab A/S (GNMSF), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Horizon Therapeutics Public (HZNP), Alnylam Pharmaceuticals (ALNY), UCB (UCBJF), Catalent (CTLT), Viatris (VTRS) and Elanco Animal Health (ELAN).
View all of GRFS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Grifols investors own include Gilead Sciences (GILD), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Abbott Laboratories (ABT), Alibaba Group (BABA), Johnson & Johnson (JNJ), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY) and Nektar Therapeutics (NKTR).

Grifols trades on the NASDAQ under the ticker symbol "GRFS."

Grifols' stock is owned by a variety of institutional and retail investors. Top institutional investors include FIL Ltd (1.21%), Black Creek Investment Management Inc. (0.69%), Goldman Sachs Group Inc. (0.69%), UBS Group AG (0.60%), Janus Henderson Group PLC (0.54%) and Baillie Gifford & Co. (0.47%).

GRFS stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, FIL Ltd, CIBC Private Wealth Group LLC, Reilly Financial Advisors LLC, Capital International Investors, Baillie Gifford & Co., GABELLI & Co INVESTMENT ADVISERS INC., and Whitebox Advisors LLC.

GRFS stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Soditic Asset Management LLP, Optiver Holding B.V., Black Creek Investment Management Inc., JPMorgan Chase & Co., Brandes Investment Partners LP, Janus Henderson Group PLC, and Morgan Stanley.

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GRFS stock can currently be purchased for approximately $17.57.

Grifols has a market capitalization of $12.08 billion and generates $6.10 billion in revenue each year. The biotechnology company earns $706.57 million in net income (profit) each year or $1.23 on an earnings per share basis.

Grifols employs 24,000 workers across the globe.

The following companies are subsidiares of Grifols: Aigües Minerals de Vilajuiga S.A., Araclon Biotech, Araclon Biotech S.L., Asociación I+D Progenika, Biomat S.A., Biomat USA Inc., Biotest Pharmaceutical Corporation, Biotest US Corporation, Chiquito Acquisition Corp., Diagnostic Grifols S.A., Goetech LLC (D/B/A Medkeeper), Gri-Cel S.A. , Grifols (H.K.) Limited, Grifols (Thailand) Ltd, Grifols Argentina S.A., Grifols Asia Pacific Pte Ltd, Grifols Australia Pty Ltd., Grifols Biologicals LLC., Grifols Brasil Lda., Grifols Canada Ltd., Grifols Chile S.A., Grifols Colombia Ltda, Grifols Deutschland GmbH, Grifols Diagnostics Equipment Taiwan Limited, Grifols Diagnostics Solutions Inc, Grifols Engineering S.A., Grifols France S.A.R.L., Grifols India Healthcare Private Ltd, Grifols Innovation and New Technologies Limited, Grifols International S.A., Grifols Italia S.p.A, Grifols Japan K.K., Grifols Malaysia Sdn Bhd, Grifols Movaco S.A., Grifols México S.A. de C.V., Grifols Nordic AB, Grifols Pharmaceutical Technology (Shanghai) Co. Ltd., Grifols Polska Sp.z.o.o., Grifols Portugal Productos Farmacéuticos e Hospitalares Lda., Grifols Shared Services North America Inc., Grifols Switzerland AG, Grifols Therapeutics LLC., Grifols UK Ltd., Grifols USA LLC., Grifols Viajes S.A., Grifols Worldwide Operations Limited, Grifols Worldwide Operations Spain S.A., Grifols Worldwide Operations USA Inc., Grifols s.r.o., Gripdan Invest S.L, Haema AG, Instituto Grifols S.A., Interstate Blood Bank Inc., Kiro Grifols S.L, Kiro Robotics, Laboratorios Grifols S.A., Logística Grifols S.A. de C.V., Medion Diagnostics GmbH, Medion Grifols Diagnostic AG, PBS Acquisition Corp., Progenika Biopharma, Progenika Biopharma S.A., Squadron Reinsurance Designated Activity Company, Talecris Biotherapeutics, Talecris Plasma Resources Inc., and VCN Bioscience S.L..

Grifols was founded in 1909.

The official website for Grifols is www.grifols.com.

Grifols is headquartered at 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174.

Grifols' mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at (493) 571-2200 or via email at [email protected]